Skinvisible, Inc. (SKVI)

OTCMKTS: SKVI · Delayed Price · USD
0.101
+0.031 (44.29%)
Apr 12, 2024, 2:21 PM EDT - Market closed
Market Cap 458.52K
Revenue (ttm) 20,000
Net Income (ttm) -5.95M
Shares Out 4.54M
EPS (ttm) -1.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,515
Open 0.101
Previous Close 0.070
Day's Range 0.101 - 0.101
52-Week Range 0.055 - 0.140
Beta -0.39
Analysts n/a
Price Target n/a
Earnings Date n/a

About SKVI

Skinvisible, Inc., together with its subsidiaries, focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over the counter, personal skincare, and cosmetic arenas. Its non-dermatological formulations offer solutions for women's health, pain management, and other markets. The company offers sunless tanning and sunscreen products. It also licenses to pharmaceutical companies; assists pharmaceutical clients in the early developmen... [Read more]

IPO Date Jan 7, 1999
Employees 2
Stock Exchange OTCMKTS
Ticker Symbol SKVI
Full Company Profile

Financial Performance

In 2022, Skinvisible's revenue was $279,296, a decrease of -57.90% compared to the previous year's $663,426. Losses were -$2.21 million, -3.26% less than in 2021.

Financial Statements

News

Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome

LAS VEGAS, NV / ACCESSWIRE / February 14, 2024 / Skinvisible, Inc. ("Skinvisible") (OTCQB:SKVI) is excited to share a promising update on the ongoing clinical trials conducted by its licensee, Quoin P...

Other symbols: QNRX
2 months ago - Accesswire

Skinvisible Announces First Invisicare Delivery Technology Product to Receive U.S. FDA Acceptance of Investigational New Drug

LAS VEGAS, NV / ACCESSWIRE / June 6, 2022 / Skinvisible, Inc. ("Skinvisible") (OTCQB:SKVI), is pleased to announce that its licensee Quoin Pharmaceuticals, Inc. ("Quoin") (NASDAQ:QNRX), has received U...

2 years ago - Accesswire